5-Mar-2025
Top Executives Cash Out on Pulmonx Stock!
TipRanks (Wed, 5-Mar 9:06 PM ET)
EDAP Appoints Glen French to Board of Directors
Globe Newswire (Mon, 3-Mar 7:00 AM ET)
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
Globe Newswire (Wed, 19-Feb 4:05 PM ET)
Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day
Globe Newswire (Thu, 13-Feb 4:05 PM ET)
Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Globe Newswire (Wed, 5-Feb 4:05 PM ET)
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Pulmonx trades on the NASDAQ stock market under the symbol LUNG.
As of March 5, 2025, LUNG stock price declined to $8.19 with 228,279 million shares trading.
LUNG has a beta of 1.46, meaning it tends to be more sensitive to market movements. LUNG has a correlation of 0.06 to the broad based SPY ETF.
LUNG has a market cap of $325.93 million. This is considered a Small Cap stock.
Last quarter Pulmonx reported $24 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.12.
In the last 3 years, LUNG traded as high as $28.30 and as low as $4.07.
The top ETF exchange traded funds that LUNG belongs to (by Net Assets): IWM, VTI, VXF, IWO, SCHA.
LUNG has underperformed the market in the last year with a return of -11.6%, while SPY returned +15.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LUNG shares. However, LUNG has outperformed the market in the last 3 month and 2 week periods, returning +25.5% and +17.2%, while SPY returned -3.7% and -4.6%, respectively. This indicates LUNG has been having a stronger performance recently.
LUNG support price is $8.20 and resistance is $9.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LUNG shares will trade within this expected range on the day.